Monitoring of anti-xa in pregnant patients with mechanical prosthetic valves receiving low-molecular-weight heparin: Peak or trough levels?

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 5, 2014, Pages 451-456

  Goland, Sorel ^a   Schwartzenberg, Shmuel ^a   Fan, John ^b   Kozak, Natasha ^a   Khatri, Nudrat ^b   Elkayam, Uri ^b  

^a HEBREW UNIVERSITY   (Israel)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Anticoagulation; Low molecular weight heparin; Mechanical prosthetic heart valves; Pregnancy

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; FEMALE; HEART ATRIUM FIBRILLATION; HEART TAMPONADE; HEMATOMA; HUMAN; INTRAUTERINE HEMATOMA; MECHANICAL HEART VALVE; MEDICAL DEVICE COMPLICATION; MITRAL VALVE REPLACEMENT; MITRAL VALVE STENOSIS; PERICARDIOCENTESIS; PREGNANT WOMAN; PRIORITY JOURNAL; PROSTHESIS THROMBOSIS; PROTEIN BLOOD LEVEL; TRANSLUMINAL VALVULOPLASTY; CALIFORNIA; DRUG EFFECTS; HEART VALVE PROSTHESIS; MEDICAL SOCIETY; PRACTICE GUIDELINE; PREGNANCY; RETROSPECTIVE STUDY;

ADULT; ANTICOAGULANTS; FACTOR XA; FEMALE; GUIDELINES AS TOPIC; HEART VALVE PROSTHESIS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LOS ANGELES; PREGNANCY; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL;

EID: 84913586139     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248414524302     Document Type: Article

References (31)

1. Elkayam U, Singh H, Irani A, Akhter MW. Anticoagulation in pregnant women with prosthetic heart valve. J Cardiovasc Pharmacol Ther. 2004;9(2):107-115.
2. McLintock C. Anticoagulant therapy in pregnant women with mechanical prosthetic heat valves: no easy option. Thromb Res. 2011;127 suppl 3:S56-S60.
3. Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: A systematic review of the literature. Arch Intern Med. 2000;160(2):191-196.
4. Kawamata K, Neki R, Yamanaka K, et al. Risks and pregnancy outcome in women with prosthetic mechanical heart valve replacement. Circ J. 2007;71(2):211-213.
5. Al-Lawati AA, Venkitraman M, Al-Delaime T, Valliathu J. Pregnancy and mechanical heart valves replacement; dilemma of anticoagulation. Eur J Cardiothorac Surg. 2002;2(2):223-227.
6. Meschengieser SS, Fondevila CG, Santarelli MT, Lazzari MA. Anticoagulation in pregnant women with mechanical heart valve prostheses. Heart. 1999;82(1):23-26.
7. Geelani MA, Singh S, Verma A, Nagesh A, Betigeri V, Nigam M. Anticoagulation in patients with mechanical valves during pregnancy. Asian Cardiovasc Thorac Ann. 2005;13(1):30-33.
8. Vitale N, De Eeo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol. 1999; 33(6):1637-1641.
9. De Santo LS, Romano G, Carte DA, et al. Mechanical aortic valve replacement in young women planning on pregnancy: Maternal and fetal outcome under low oral anticoagulation. A pilot observational study on comprehensive preoperative counseling protocol. J Am Coll Cardiol. 2012;59(12):1110-1105.
10. Sillesen M, Hjortdal V, Vejlstrup N, Sørensen K. Pregnancy with prosthetic heart valves-30 years' nationwide experience in Denmark. Eur J Cardiothorac Surg. 2011;40(2):448-454.
11. Shannon MS, Edwards MB, Long F, Taylor KM, Bagger JP, De Swiet M. Anticoagulant management of pregnancy following heart valve replacement in the United Kingdom, 1986-2002. J Heart Valve Dis. 2008;17(5):526-532.
12. Sadler L, MeCowan L, White H, Stewart A, Bracken M, North R. Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homogralt valves. Br J Obstet Gynecol. 2000;107(2):245-253.
13. James AH. Venous thromboembolism in pregnancy. Arterioscler Thromb Vasc Biol. 2009;29(3):326-331.
14. Rowan JA, McCowan LM, Raudkivi PJ, North RA. Enoxaparin treatment in women with mechanical heart valves during pregnancy. Am J Obstet Gynecol. 2001;185(3):633-637.
15. Arnaout MS, Kazma H, Khalil A, et al. Is there a safe anticoagulation protocol for pregnant women with prosthetic valves. Clin Exp Obst Gyn. 1998;25(3):101-104.
16. Oran B, Lee-Parritz A, Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost. 2004;92(4):747-751.
17. Yinon Y, Siu SC, Warshafsky C, et al. Use of low molecular weight heparin in pregnant women with mechanical heart valves. Am J Cardiol. 2009;104(9):1259-1263.
18. Abildgaard U, Sandset PM, Hammerstrom J, Gjestvang FT, Tveit A. Management of pregnant women with mechanical heart valve prosthesis: Thromboprophylaxis with low molecular weight heparin. Thromb Res. 2009;124(3):262-267.
19. Quinn J, Von Klemperer K, Brooks R, Peebles D, Walker F, Cohen H. Use of high intensity adjusted dose low molecular weight heparin in women with mechanical heart valves during pregnancy: A single-center experience. Haematologica. 2009; 94(11):1608-1612.
20. McLintock C, McCowan LM, North RA. Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin. BJOG. 2009; 116(12):1585-1592.
21. Elkayam U, Bitar F. Valvular heart disease and pregnancy: prosthetic valves part II. J Am Coll Cardiol. 2005;46(3):403-410.
22. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidencebased clinical practice guidelines. Chest. 2012;141(2 suppl): e691S-e736S.
23. Bonow RO, Carabello BA, Chatterjee K, et al. American College of Cardiology/American Heart Association Task Force on practice guidelines. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the society of cardiovascular anesthesiologists, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol. 2008;52(13):e1-e142.
24. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: The task force on the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(24):3147-3197.
25. Lovenox Injection [package insert]. Bridgewater, NJ: Aventis Pharmaceuticals, 2004.
26. Gausman JN, Richard AM. Inaccuracy of a "spiked curve" for monitoring unfractionated heparin therapy. Am J Clin Pathol. 2011;135(6):870-876.
27. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997; 337(10):688-698.
28. Goland S, Elkayam U. Anticoagulation in pregnancy. Cardiol Clin. 2012;30(3):395-405.
29. Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol. 2004;191(3):1024-1029.
30. Friedrich E, Hameed AB. Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy. J Perinatol. 2010;30(4):253-257.
31. Vijayan V, Rachel T. Pregnancy outcomes compared in women with mechanical heart valve replacements anticoagulated with warfarin and enoxaparin in pregnancy. Med J Malaysia. 2012; 67(6):591-594.